Loading…
Verastem, Inc. is projected to rise to $6.03 by 2027, a +9% move from its current price of $5.53. VSTM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.29 | $5.53 | $5.78 | -0.03% |
| Jul 14 | $5.19 | $5.53 | $5.89 | -0.06% |
| Jul 15 | $5.11 | $5.53 | $5.97 | -0.08% |
| Jul 16 | $5.05 | $5.52 | $6.04 | -0.11% |
| Jul 17 | $5.00 | $5.52 | $6.10 | -0.14% |
| Jul 18 | $4.95 | $5.52 | $6.16 | -0.17% |
| Jul 19 | $4.90 | $5.52 | $6.21 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.90 | $5.52 | $6.21 | -0.20% |
| Week 2 | $4.66 | $5.51 | $6.51 | -0.39% |
| Week 3 | $4.48 | $5.50 | $6.75 | -0.59% |
| Week 4 | $4.33 | $5.49 | $6.96 | -0.78% |
| Week 5 | $4.20 | $5.48 | $7.14 | -0.98% |
| Week 6 | $4.09 | $5.47 | $7.31 | -1.17% |
| Week 7 | $3.99 | $5.45 | $7.46 | -1.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Verastem, Inc. is a development-stage biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally administered, small molecule dual RAF/MEK inhibitor designed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Verastem is engaged in multiple clinical studies, including RAMP 301, a randomized global confirmatory trial evaluating the combination of Avutometinib and Defactinib for recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open-label trial evaluating Avutometinib alone and in combination with Defactinib; and FRAME, investigating Avutometinib and Defactinib in KRAS mutant cancers with subsequent analyses; and RAMP 205. The company has license agreements with Chugai Pharmaceutical Co., Ltd. and Pfizer Inc., and a clinical collaboration with Amgen, Inc.
to evaluate the combination of Avutometinib with Amgen’s LUMAKRAS KRAS-G12C inhibitor, among other collaborations. The assets and programs mention additional partnerships and development efforts, including VS-7375 collaborations and AVMAPKI/FAKZYNJA CO-PACK arrangements for Avutometinib and Defactinib. Headquartered in Needham, MA, Verastem operates in the healthcare sector as a biotechnology developer.
Verastem, Inc. trades under the symbol VSTM and currently prices at $5.40. Its market capitalization stands at $474.52M, with a market ranking of 3103. The stock sits within a broader price framework that shows bullish near-term technical cues but with notable risk given the variability often seen in development-stage biopharmaceuticals.
The long-run outlook provided by the consensus forecast suggests substantial upside potential, with average prices rising meaningfully from 2026 through 2050, though individual year outcomes vary and are not guarantees.
In the near term, the stock’s price activity is framed by a 30-day range, with a low of $3.99 and a high of $7.31, and a nearby resistance at $5.40 against a support level of $3.45. These levels help define the range within which the price may traverse in the months ahead, while the current price sits around the middle of that context.
A major floor 50.2% below — a decisive break under it would weaken the trend.
The nearest floor, 37.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 25.1% above — clearing it would confirm fresh momentum.
Key VSTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VSTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.06 | Buy | $5.11 | Buy |
| MA 10 | $4.53 | Buy | $4.75 | Buy |
| MA 20 | $4.27 | Buy | $4.47 | Buy |
| MA 50 | $4.45 | Buy | $4.58 | Buy |
| MA 100 | $5.11 | Buy | $5.14 | Buy |
| MA 200 | $6.67 | Sell | $5.86 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 71.98 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 200.25 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | 31.35 | Buy |
| Bollinger %B (20,2) | 1.08 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 0.90 | Buy |
| Ultimate (7,14,28) | 85.49 | Sell |
| Momentum (10) | 2.08 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 5.57 | Sell |
| ADX (14) | 23.42 | Buy |
| ATR (14) | 0.19 | Info |
The 30-day technical picture shows a bullish tilt in sentiment with an RSI of 70. The stock’s 50-day simple moving average sits at $4.45, while the 200-day simple moving average is at $6.68, signaling a potential long-term resistance around the $6.68 area if momentum continues. Support is identified near $3.45 and resistance at $5.40, with the 30-day trading range between $3.99 and $7.31.
These metrics suggest a window of consolidation near the current price with upside potential if the resistance at $5.40 is breached.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.45 | $5.53 | $6.96 | 0% | Neutral | |
| $4.52 | $6.03 | $8.67 | +9% | Neutral | |
| $4.21 | $5.91 | $8.98 | +7% | Neutral | |
| $5.51 | $8.06 | $12.78 | +46% | Bullish | |
| $6.85 | $10.40 | $17.08 | +88% | Bullish | |
| $7.26 | $11.41 | $19.33 | +106% | Bullish | |
| $7.46 | $12.12 | $21.11 | +119% | Bullish | |
| $6.86 | $11.50 | $20.53 | +108% | Bullish | |
| $7.07 | $12.20 | $22.27 | +121% | Bullish | |
| $8.12 | $14.43 | $26.88 | +161% | Bullish | |
| $10.69 | $21.82 | $44.28 | +295% | Bullish | |
| $24.57 | $54.59 | $125.03 | +887% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.45 | $5.53 | $6.54 | +0.00% |
| August 2026 | $4.35 | $5.22 | $6.50 | -5.59% |
| September 2026 | $4.44 | $5.39 | $6.83 | +3.24% |
| October 2026 | $4.43 | $5.43 | $6.99 | +0.80% |
| November 2026 | $4.21 | $5.21 | $6.79 | -4.07% |
| December 2026 | $4.23 | $5.28 | $6.96 | +1.36% |
Click any year to see its month-by-month VSTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VSTM price prediction for 2026 points to an average of $5.53 (low $3.45, high $6.96) — a potential gain of 0% on today's $5.53. A consolidation phase looks the most probable path here.
In 2027, VSTM is projected to trade between $4.52 and $8.67, averaging $6.03 — a potential gain of +9% from today's $5.53. That is up +9% on the projected 2026 average. Price action looks broadly range-bound.
Verastem, Inc.'s 2028 outlook centres on $5.91, within a $4.21 to $8.98 range. That is -2% versus the projected 2027 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, VSTM could reach as high as $12.78, with a base case around $8.06 and support toward $5.51 — roughly +46% from $5.53. Momentum favours further upside here.
Expect VSTM to range from $6.85 to $17.08 through 2030. The $10.40 average target implies a +88% move from current prices. That is up +29% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The VSTM price prediction for 2031 points to an average of $11.41 (low $7.26, high $19.33) — a potential gain of +106% on today's $5.53. Momentum favours further upside here.
In 2032, VSTM is projected to trade between $7.46 and $21.11, averaging $12.12 — a potential gain of +119% from today's $5.53. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Verastem, Inc.'s 2033 outlook centres on $11.50, within a $6.86 to $20.53 range. That is -5% versus the projected 2032 average. That marks a +108% change versus current levels. Momentum favours further upside here.
By 2034, VSTM could reach as high as $22.27, with a base case around $12.20 and support toward $7.07 — roughly +121% from $5.53. Buyers look set to stay in control over this stretch.
Expect VSTM to range from $8.12 to $26.88 through 2035. The $14.43 average target implies a +161% move from current prices. That is up +18% on the projected 2034 average. Momentum favours further upside here.
The VSTM price prediction for 2040 points to an average of $21.82 (low $10.69, high $44.28) — a potential gain of +295% on today's $5.53. Buyers look set to stay in control over this stretch.
In 2050, VSTM is projected to trade between $24.57 and $125.03, averaging $54.59 — a potential gain of +887% from today's $5.53. That is up +150% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VSTM today (≈ 180.831826 VSTM) could be worth
$9,872.28
+$8,872.28 (+887%) by 2050 · US Dollar
Based on the average projected VSTM price of $54.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VSTMwould be worth at today's price.
$1,000 invested in VSTM on Jul 10, 2025 (≈ 210.970474 VSTM) would be worth
$1,166.67
+$166.67 (+16.7%) today · 1.17× · US Dollar
Based on a VSTM entry price of $4.74 vs. today's $5.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.5 | $1,228.89 | +22.9% |
| 1 month ago | $3.76 | $1,470.74 | +47.1% |
| 3 months ago | $5.31 | $1,041.43 | +4.1% |
| 6 months ago | $7.11 | $777.78 | -22.2% |
| 1 year ago | $4.74 | $1,166.67 | +16.7% |
| All time (5.0y) ago | $44.04 | $125.57 | -87.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VSTM forecast.
Our base-case forecast reaches $11.00 around 2031.
Implied market cap at $11.00: $966.61M
Forecasts project a multi-year upward trajectory with varying year-by-year targets and ROI figures. For 2026, the min, avg, and max prices are $3.45, $5.40, and $6.81 respectively, with a neutral sentiment and an ROI of 0. By 2027, the min/avg/max reach $4.35/$5.84/$8.44 with an ROI of 8.1 and a neutral stance.
The 2028 path shows $3.99/$5.63/$8.60 and a 4.2 ROI, still considered neutral. In 2029, the forecast rises to $5.25/$7.73/$12.35 with a 43.2 ROI and a bullish tilt. The 2030 forecast strengthens to $6.52/$9.99/$16.54 with an 84.9 ROI and bullish sentiment.
Through 2031–2035, the avg prices rise to $10.88 (2031), $11.59 (2032), $10.89 (2033), $11.48 (2034), and $13.65 (2035) with corresponding ROIs of 101.5, 114.6, 101.7, 112.6, and 152.8, all carrying bullish sentiment. By 2040, the avg price is forecast at $20.38 with a max of $41.82 and a 277.4 ROI, still bullish. The 2050 outlook is the strongest, with min/$23.06, avg $51.25, max $117.88 and a 849.1 ROI, remaining bullish.
These figures illustrate meaningful upside potential across the horizon, tempered by the inherent uncertainty of development-stage therapeutics.
Tap a question to reveal the answer.
2030 forecast: min $6.52, avg $9.99, max $16.54 with ROI 84.9 and sentiment BULLISH.
The forecast shows a neutral stance in 2026, turning bullish in later years, with notable upside by 2030 (avg $9.99, ROI 84.9) and especially strong potential in 2040 (avg $20.38, ROI 277.4) and 2050 (avg $51.25, ROI 849.1). However, these are estimates and not guarantees.
Yes: 2032 max is $20.36 and 2032 avg is $11.59; by 2040 the avg is $20.38 and the max $41.82, with a 277.4 ROI.
Current price is $5.40. The 30-day range is $3.99 to $7.31, with support at $3.45 and resistance at $5.40.
2050 forecast: min $23.06, avg $51.25, max $117.88 with ROI 849.1 and sentiment BULLISH.
Verastem, Inc. Community Discussion
0Share your Verastem, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.